Andersons pediatric cardiology 2115
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (60.59 KB, 3 trang )
care.Withthissystematicreview,theauthors
illustratehowtoapproachinvestigationsrelated
topediatricpharmacogenomicswhenlimited
dataisavailable,usingstatinsastheexample..
LeederJS,BrownJT,SodenSE.Individualizing
theuseofmedicationsinchildren:making
goldilockshappy.ClinPharmacolTher.
2014;96(3):304–306.
Thiseditorialarticlefromleadingresearchersand
providersinprecisionmedicineillustratehowto
characterizethedose-responserelationshipin
children.Throughexamplestheyapproachhow
reducingvaraibilityinexposurethrough
genotype-baseddosingcouldindividualizecare
andimproveoutcomes..
WagnerJ,Abdel-RahmanSM.Pediatric
pharmacokinetics.PediatrRev.2013;34(6):258–
269.
Thisreviewillustratesthebasicprinciplesof
pharmacokineticsanddrugdispositionto
considerwhenselectingdrugsanddosingin
childrenandadolescents..
RitschelW,KearnsGL.HandbookofBasic
Pharmacokinetics-IncludingClinical
Applications.7thed.AmericanPharmacist
Association:Washington,DC;2009.
Thistextbookisacomprehensivereviewof
pharmacokineticsandpossibleclinical
applications..
LeederJS,KearnsGL,SpielbergSP,vanden
AnkerJ.Understandingtherelativerolesof
pharmacogeneticsandontogenyinpediatric
drugdevelopmentandregulatoryscience.JClin
Pharmacol.2010;50(12):1377–1387.
Thiscomprehensivereviewdisplaysasystemic
approachtoascertainthecontributionsof
ontogeny(development)andgeneticvariation
thatinfluencethedose-exposure-response
relationshipforpediatric
pharmacotherapeutics..
ZangerUM,FischerJ,RaimundoS,etal.
Comprehensiveanalysisofthegeneticfactors
determiningexpressionandfunctionofhepatic
CYP2D6.Pharmacogenetics.2001;11(7):573–
585.
Thismanuscriptfrominternationally-known
expertsonthehighlypolymorphiccytochrome
2D6(CYP2D6)describesthegeneticfactorsthat
influenceCYP2D6expressionandfunction..
KoukouritakiSB,ManroJR,MarshSA,etal.
Developmentalexpressionofhumanhepatic
CYP2C9andCYP2C19.JPharmacolExpTher.
2004;308(3):965–974.
Thisresearchfromawell-respectedgroupof
developmentalpharmacologistverifiesthe
ontogenyofCYP2Csubfamily(CYP2C9and
CYP2C19)anddescribesthevarabilityof
expressionearlyinlife..
TreluyerJM,GueretG,CheronG,SonnierM,
CresteilT.DevelopmentalexpressionofCYP2C
andCYP2C-dependentactivitiesinthehuman
liver:in-vivo/in-vitrocorrelationand
inducibility.Pharmacogenetics.1997;7(6):441–
452.
Thisresearchwasfromoneoftheearliestgroups
thatdescribedtheontogenyofhepaticCYP2C
subfamilyandhowitcorrelatedwithadult
expression..
PaineMF,HartHL,LudingtonSS,etal.The
humanintestinalcytochromeP450“pie”.Drug
MetabDispos.2006;34(5):880–886.
Thispivotalresearchdescribestheexpressionof
cytochromep450(CYP)enzymeswithinthe
humanintestinaltract.Thisvalueabledata
highlightstherolethatthehumanintestinehas
withdrugbiotransformation..
deWildtSN,KearnsGL,LeederJS,vanden
AnkerJN.Glucuronidationinhumans.
Pharmacogeneticanddevelopmentalaspects.
ClinPharmacokinet.1999;36(6):439–452.
Thiscomprehensivereviewillustratesanotherclass
